Home・Список акций・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

14.93 2.47

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

14.47

Макс.

14.8

Ключевые показатели
By Trading Economics
Доход	-176M 34M
Продажи	591K 78M
P/E Средняя по отрасли	7.112 64.641
Прибыль на акцию	0.25
Рентабельность продаж	44.212
Сотрудники	128
EBITDA	2.7M 50M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+7.55% upside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-92M 2B
Предыдущая цена открытия	12.46
Предыдущая цена закрытия	14.93

Новостные настроения

By Acuity

50%

151 / 340 Рейтинг в Healthcare

Aurinia Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 авг. 2026 г., 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 июл. 2026 г., 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 июл. 2026 г., 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 июл. 2026 г., 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 июл. 2026 г., 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 июл. 2026 г., 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 июл. 2026 г., 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 июл. 2026 г., 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 июл. 2026 г., 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 июл. 2026 г., 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Сравнение c конкурентами

Изменение цены

Aurinia Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

7.55% рост

Прогноз на 12 месяцев

Средняя 15.67 USD 7.55%

Максимум 17 USD

Минимум 15 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Aurinia Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

Покупка

Удержание

Продажа

Основано на мнении 3 аналитиков, присваивавших рейтинги акциям Aurinia Pharmaceuticals Inc – Данные за последние 3 месяца.

Настроения

By Acuity

151 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.